Navigation Links
Nanoparticles help Mayo Clinic researcher deliver steroids to retina
Date:12/13/2011

ROCHESTER, Minn. -- Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A study by investigators at Mayo Clinic, Wayne State University and Johns Hopkins Medicine shows that steroids attached to the dendrimers target the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision. The findings appear in the journal Biomaterials.

Dry age-related macular degeneration and retinitis pigmentosa are caused by neuroinflammation, which progressively damages the retina and can lead to blindness. Macular degeneration is the primary cause of vision loss in older Americans, affecting more than 7 million people, according to the National Institutes of Health. Retinitis pigmentosa encompasses many genetic conditions affecting the retina and impacts 1 in 4,000 Americans, the NIH estimates.

"There is no cure for these diseases," says Mayo Clinic ophthalmologist Raymond Iezzi, M.D., a lead author of the study. "An effective treatment could offer hope to hundreds of millions of patients worldwide."

Iezzi and fellow principal author Rangaramanujam Kannan, Ph.D., an ophthalmology professor at The Wilmer Eye Institute of Johns Hopkins, developed an intracellular, sustained-release drug delivery system. The research, conducted in part at Wayne State University's Kresge Eye Institute with collaboration from Wayne State's College of Engineering and Ligon Research Center of Vision, tested the dendrimer delivery system in rats that develop neuroinflammation.

The target was microglial cells, inflammatory cells in charge of cleaning up dead and dying material in the eye, Dr. Iezzi says. When activated as "trash collectors," the cells cause damage via neuroinflammation -- a hallmark of each disease. The microglial cells gobble up the dendrimers, and the drug then shuts down the cells' activity.

"Surprisingly, the activated microglia in the degenerating retina appeared to eat the dendrimer selectively, and retain them for at least a month. The drug is released from the dendrimer in a sustained fashion inside these cells, offering targeted neuroprotection to the retina," Kannan says.

The treatment reduced neuroinflammation in the rat model and protected vision by preventing injury to photoreceptors in the retina. Though the steroid offers only temporary protection, the treatment as a whole provides sustained relief from neuroinflammation.


'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Nanoparticles help researchers deliver steroids to retina
2. New device uses gold nanoparticles to test for lung cancer
3. Study indicates nanoparticles could help pain-relieving osteoarthritis drugs last longer
4. Consumers close encounters with nanoparticles
5. UGA researchers use gold nanoparticles to diagnose flu in minutes
6. Gold nanoparticles bring scientists closer to a treatment for cancer
7. Gold nanoparticles help earlier diagnosis of liver cancer
8. Nanoparticles disguised as red blood cells will deliver cancer-fighting drugs
9. Research creates nanoparticles perfectly formed to tackle cancer
10. Good cholesterol nanoparticles seek and destroy cancer cells
11. Research provides new findings on drug delivery with nanoparticles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... 26, 2017 , ... Dr. Kovatis, is a Hospital for ... and Foot Section of the Department of Orthopedic Surgery at Hackensack University Medical ... UMC performing total ankle replacements. Because of this, Dr. Kovatis is often referred ...
(Date:9/26/2017)... Milford, PA (PRWEB) , ... September 26, 2017 , ... ... month in Chicago, called “The Magic of Fat,” revealed not only the latest about ... might prove to be an evolution in cosmetic medicine. , “Fat really is magical, ...
(Date:9/26/2017)... ... September 26, 2017 , ... The Organizing Committee ... tactical plans for Pittcon 2018. As of July 1, Adrian C. Michael, Ph.D. ... named vice president, Charles Gardner, (ChemImage Corporation) and selected chairs. , ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding Strength and Comfort ... “Good Morning Sunshine!: Finding Strength and Comfort in God” is the creation of published ... Hays Sate University, who has worked at a local mental health center for over ...
(Date:9/26/2017)... ... ... “Sound of My Song”: an intriguing and thought-provoking on love, life, and ... retired teacher with a passion for music and ancestral history. , Published by ... loss, living with depression, and finding love through the journey. There is powerful imagery ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... Lilly and Company (NYSE: LLY ) will ... an investigational, oral, first-in-class molecule for the acute treatment ... placebo in the Phase 3 SPARTAN study. Detailed results ... the International Headache Society (IHC) in Vancouver ... lasmiditan,s potential to reduce pain and provide freedom from ...
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
Breaking Medicine Technology: